Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has granted stock options to its new Chief Development Officer, Dr. Michael Rosol.
The equity award consists of options to purchase 30,000 shares of company common stock, with a four-year vesting schedule. One-fourth of the options will vest on the first anniversary, followed by equal monthly installments thereafter. The exercise price is set at the closing price of PSTV's common stock on February 28, 2025.
The options, granted outside the Company's 2020 Incentive Plan but with similar terms, are subject to Dr. Rosol's continued employment. The company has filed a Form S-8 for these equity awards, aiming to align the executive's interests with shareholders.
Plus Therapeutics (PSTV), un'azienda farmaceutica in fase clinica focalizzata su radioterapici mirati per i tumori del sistema nervoso centrale, ha concesso opzioni azionarie al suo nuovo Chief Development Officer, il Dr. Michael Rosol.
Il premio azionario consiste in opzioni per acquistare 30.000 azioni del comune stock dell'azienda, con un piano di maturazione di quattro anni. Un quarto delle opzioni maturerà al primo anniversario, seguito da rate mensili uguali in seguito. Il prezzo di esercizio è fissato al prezzo di chiusura delle azioni comuni di PSTV il 28 febbraio 2025.
Le opzioni, concesse al di fuori del Piano Incentivi 2020 dell'azienda ma con termini simili, sono soggette alla continuazione dell'impiego del Dr. Rosol. L'azienda ha presentato un Modulo S-8 per questi premi azionari, con l'obiettivo di allineare gli interessi dell'esecutivo con quelli degli azionisti.
Plus Therapeutics (PSTV), una empresa farmacéutica en etapa clínica centrada en radioterapéuticos dirigidos para cánceres del sistema nervioso central, ha otorgado opciones sobre acciones a su nuevo Director de Desarrollo, el Dr. Michael Rosol.
El premio en acciones consiste en opciones para comprar 30,000 acciones del stock común de la empresa, con un calendario de adquisición de cuatro años. Una cuarta parte de las opciones se adquirirá en el primer aniversario, seguido de cuotas mensuales iguales a partir de entonces. El precio de ejercicio se establece al precio de cierre de las acciones comunes de PSTV el 28 de febrero de 2025.
Las opciones, otorgadas fuera del Plan de Incentivos 2020 de la empresa pero con términos similares, están sujetas a la continuidad del empleo del Dr. Rosol. La empresa ha presentado un Formulario S-8 para estos premios en acciones, con el objetivo de alinear los intereses del ejecutivo con los de los accionistas.
Plus Therapeutics (PSTV)는 중추신경계 암을 위한 표적 방사선치료에 중점을 두고 있는 임상 단계의 제약회사로, 새로운 개발 책임자인 Michael Rosol 박사에게 주식 옵션을 부여했습니다.
주식 보상은 회사의 보통주 30,000주를 구매할 수 있는 옵션으로 구성되어 있으며, 4년의 베스팅 일정이 있습니다. 옵션의 1/4은 첫 번째 기념일에 베스팅되며, 이후 매달 동일한 금액으로 베스팅됩니다. 행사 가격은 2025년 2월 28일 PSTV의 보통주 종가로 설정됩니다.
이 옵션은 회사의 2020 인센티브 계획 외부에서 부여되지만 유사한 조건을 가지고 있으며, Rosol 박사의 계속된 고용에 따라 달라집니다. 회사는 이러한 주식 보상을 위해 S-8 양식을 제출했으며, 이는 경영진의 이해관계를 주주와 일치시키기 위한 것입니다.
Plus Therapeutics (PSTV), une entreprise pharmaceutique en phase clinique axée sur les radiothérapies ciblées pour les cancers du système nerveux central, a accordé des options d'achat d'actions à son nouveau Directeur du Développement, le Dr Michael Rosol.
La récompense en actions consiste en des options d'achat de 30 000 actions ordinaires de la société, avec un calendrier d'acquisition de quatre ans. Un quart des options sera acquis lors du premier anniversaire, suivi de versements mensuels égaux par la suite. Le prix d'exercice est fixé au prix de clôture des actions ordinaires de PSTV au 28 février 2025.
Les options, accordées en dehors du Plan d'Incitation 2020 de l'entreprise mais avec des conditions similaires, sont soumises à la poursuite de l'emploi du Dr Rosol. L'entreprise a déposé un formulaire S-8 pour ces récompenses en actions, visant à aligner les intérêts du dirigeant avec ceux des actionnaires.
Plus Therapeutics (PSTV), ein pharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Radiotherapeutika für Krebs im zentralen Nervensystem konzentriert, hat seinem neuen Chief Development Officer, Dr. Michael Rosol, Aktienoptionen gewährt.
Die Aktienvergütung besteht aus Optionen zum Kauf von 30.000 Aktien des Stammkapitals des Unternehmens, mit einem vierjährigen Vesting-Zeitplan. Ein Viertel der Optionen wird am ersten Jahrestag fällig, gefolgt von gleichmäßigen monatlichen Raten danach. Der Ausübungspreis wird auf den Schlusskurs der Stammaktien von PSTV am 28. Februar 2025 festgelegt.
Die Optionen, die außerhalb des Incentive-Plans 2020 des Unternehmens gewährt wurden, jedoch mit ähnlichen Bedingungen, unterliegen der fortgesetzten Anstellung von Dr. Rosol. Das Unternehmen hat ein Formular S-8 für diese Aktienvergütungen eingereicht, um die Interessen des Executives mit den Interessen der Aktionäre in Einklang zu bringen.
- New Chief Development Officer hired to strengthen executive team
- Stock options align management interests with shareholders
- Potential shareholder dilution from 30,000 new stock options
HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on February 28, 2025, it granted option awards to Dr. Michael Rosol, the Company’s new Chief Development Officer. The Company agreed to grant these equity awards to Dr. Rosol to induce him to commence employment with the Company.
The approved option awards are options to purchase up to 30,000 shares of the common stock of the Company. The options are scheduled to vest over four years, with one-fourth of the options vesting on the first anniversary of the grant date with the remaining options vesting thereafter in equal monthly installments. The vesting of the options is also subject to certain requirements, including Dr. Rosol’s continued service as an employee of the Company through the applicable vesting dates. The exercise price of the options is equal to the closing price of the Company’s common stock on February 28, 2025, the grant date.
The Company believes that these equity grants create a strong alignment of interests between Dr. Rosol and Company shareholders. The equity awards were granted outside of the Company’s 2020 Incentive Plan but generally have terms and conditions consistent with those set forth in that plan. The Company has filed a Form S-8 covering these equity awards.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
How many stock options did Plus Therapeutics (PSTV) grant to Dr. Michael Rosol?
What is the vesting schedule for Dr. Rosol's stock options at Plus Therapeutics?
When was the exercise price for PSTV's new stock options determined?
What position did Dr. Michael Rosol take at Plus Therapeutics (PSTV)?
